Edition:
United Kingdom

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

16.55USD
20 Feb 2018
Change (% chg)

$-1.02 (-5.81%)
Prev Close
$17.57
Open
$17.39
Day's High
$17.51
Day's Low
$16.44
Volume
28,523
Avg. Vol
47,177
52-wk High
$23.36
52-wk Low
$8.00

Chart for

About

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing... (more)

Overall

Beta: --
Market Cap(Mil.): $317.10
Shares Outstanding(Mil.): 16.90
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Protagonist Therapeutics Granted Two New US Patents For Peptide Drug Candidates PTG-100 And PTG-300

* PROTAGONIST THERAPEUTICS GRANTED TWO NEW US PATENTS FOR PEPTIDE DRUG CANDIDATES PTG-100 AND PTG-300 Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-Protagonist Therapeutics Appoints Sarah Noonberg To Board

* PROTAGONIST THERAPEUTICS APPOINTS SARAH NOONBERG TO THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

14 Dec 2017

BRIEF-Protagonist Therapeutics Announces Final Phase 1 Study Results With Novel Hepcidin Mimetic, PTG-300

* PROTAGONIST THERAPEUTICS ANNOUNCES FINAL PHASE 1 STUDY RESULTS WITH NOVEL HEPCIDIN MIMETIC, PTG-300

14 Dec 2017

BRIEF-Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200

* Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200

09 Nov 2017

BRIEF-Protagonist Therapeutics Q3 ‍net loss per share $0.29​

* Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update

06 Nov 2017

BRIEF-Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share

* Says public offering of 3.53 million common shares priced at $17.00 per share Source text for Eikon: Further company coverage:

12 Oct 2017

BRIEF-Protagonist Therapeutics announces proposed public offering of common stock

* Protagonist Therapeutics announces proposed public offering of common stock

11 Oct 2017

BRIEF-Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​

* Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​ Source text: (http://bit.ly/2xDBQBh) Further company coverage:

01 Sep 2017

BRIEF-Protagonist Therapeutics announces closing of Janssen license

* Protagonist Therapeutics announces closing of Janssen license and collaboration agreement for PTG-200 and receipt of $50 million payment

24 Aug 2017

Earnings vs. Estimates